These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 8707165)

  • 1. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans.
    Frydman A
    Haemostasis; 1996; 26 Suppl 2():24-38. PubMed ID: 8707165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacokinetics of LMWHs.
    Samama MM; Gerotziafas GT
    Semin Thromb Hemost; 2000; 26 Suppl 1():31-8. PubMed ID: 11011804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
    Collignon F; Frydman A; Caplain H; Ozoux ML; Le Roux Y; Bouthier J; Thébault JJ
    Thromb Haemost; 1995 Apr; 73(4):630-40. PubMed ID: 7495071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of low molecular weight heparins in animal models.
    Fareed J; Fu K; Yang LH; Hoppensteadt DA
    Semin Thromb Hemost; 1999; 25 Suppl 3():51-5. PubMed ID: 10549716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile.
    Fareed J; Hoppensteadt D; Schultz C; Ma Q; Kujawski MF; Neville B; Messmore H
    Curr Pharm Des; 2004; 10(9):983-99. PubMed ID: 15078128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profile of different low-molecular weight heparins used at therapeutic dose.
    Gouin-Thibault I; Pautas E; Siguret V
    Drug Saf; 2005; 28(4):333-49. PubMed ID: 15783242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy?
    Andrassy K; Eschenfelder V
    Thromb Res; 1996; 81(2 Suppl):S29-38. PubMed ID: 8822125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of low-molecular-weight heparins in cardiovascular disease.
    Verhaeghe R
    Acta Cardiol; 1998; 53(1):15-21. PubMed ID: 9638965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human pharmacokinetics of low molecular weight heparins.
    Cornelli U; Fareed J
    Semin Thromb Hemost; 1999; 25 Suppl 3():57-61. PubMed ID: 10549717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route.
    Hiebert LM; Wice SM; Ping T
    Biomed Pharmacother; 2004; 58(6-7):372-80. PubMed ID: 15271419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases.
    Agnelli G; Iorio A; Renga C; Boschetti E; Nenci GG; Ofosu FA; Hirsh J
    Circulation; 1995 Nov; 92(10):2819-24. PubMed ID: 7586247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
    Martineau P; Tawil N
    Ann Pharmacother; 1998 May; 32(5):588-98, 601. PubMed ID: 9606481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bemiparin: pharmacological profile.
    Sánchez-Ferrer CF
    Drugs; 2010 Dec; 70 Suppl 2():19-23. PubMed ID: 21162606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
    Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin.
    Hoppensteadt DA; Jeske W; Fareed J; Bermes EW
    Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S57-64. PubMed ID: 7647223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on heparins at the beginning of the new millennium.
    Fareed J; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic activity and its relationship to in vitro anticoagulant effects.
    Gray E; Padilla A; Barrowcliffe TW
    Haemostasis; 1993 Mar; 23 Suppl 1():99-102. PubMed ID: 8388358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disorders.
    Mousa SA
    Semin Thromb Hemost; 2000; 26 Suppl 1():39-46. PubMed ID: 11011805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.